Collplant Holdings (CLGN) AI Stock Analysis

• Market Cap: $31.28M
• Dividend Yield: N/A
• Average Volume (3M): 173.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: 248.62%
• EPS Growth: 26.22%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 12,716,014
• 10 Day Avg. Volume: 479,959
• 30 Day Avg. Volume: 173,275
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 14.41
• Enterprise Value/Gross Profit: -5.34
• Enterprise Value/Ebitda: -0.46
• 1Y Price Target: $11.00
• Price Target Upside: 358.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: $2.50 ▲(4.17% Upside)

Collplant Holdings' overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow challenges. While there is some technical strength, the negative valuation metrics further weigh down the score, indicating a high-risk investment.

Positive Factors

Product Innovation

The advancement of CollPlant's photocurable dermal filler into clinical trials signifies a strong pipeline in regenerative medicine, potentially enhancing market position and driving future revenue growth.

Market Expansion

Expanding the distribution network for Vergenix STR in Europe enhances CollPlant's market presence, potentially increasing sales and solidifying its position in the regenerative medicine sector.

Strategic Leadership

Strengthening leadership in North America with an experienced VP enhances commercial strategy, potentially boosting sales and market penetration for rhCollagen-based products.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in product sales and market demand, potentially impacting long-term financial stability and growth prospects.

Negative Cash Flow

Deteriorating cash flow limits operational flexibility and investment capacity, posing risks to sustaining business operations and funding future growth initiatives.

Financial Instability

Decreasing assets and equity suggest weakening financial health, potentially affecting the company's ability to secure financing and invest in growth opportunities.

Collplant Holdings Business Overview & Revenue Model

Company Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

How the Company Makes Money

Collplant generates revenue through the commercialization of its collagen-based products and therapies. Its primary revenue streams include sales of medical devices and therapeutic products designed for wound care and tissue regeneration. Additionally, the company may engage in strategic partnerships with other healthcare firms, research institutions, and pharmaceutical companies to co-develop products or license its technology, further enhancing its revenue potential. Collaborations and partnerships may also provide funding through grants or milestone payments, contributing to its overall earnings. The company's focus on developing novel applications of its collagen technology positions it to capitalize on growing market demands in the regenerative medicine field.

Collplant Holdings Financial Statement Overview

Summary

Collplant Holdings is facing significant financial challenges, with a drastic revenue decline, negative profit margins, and deteriorating cash flow. Despite low debt levels, the company's shrinking asset base and equity indicate financial instability.

Income Statement

Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.

Cash Flow

Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	515.00K	10.96M	299.00K	15.64M	6.14M
Gross Profit	-1.11M	8.97M	-101.00K	13.64M	3.13M
EBITDA	-16.21M	-6.41M	-16.02M	838.00K	-4.94M
Net Income	-16.61M	-7.02M	-16.75M	409.00K	-5.81M
Balance Sheet
Total Assets	18.71M	34.13M	37.77M	51.22M	10.84M
Cash, Cash Equivalents and Short-Term Investments	11.91M	26.67M	29.65M	43.30M	3.33M
Total Debt	3.08M	3.16M	2.91M	3.61M	3.39M
Total Liabilities	5.25M	5.79M	5.49M	6.10M	6.36M
Stockholders Equity	13.46M	28.34M	32.28M	45.12M	4.48M
Cash Flow
Free Cash Flow	-14.58M	-3.72M	-15.01M	912.00K	-4.97M
Operating Cash Flow	-14.09M	-2.76M	-13.70M	2.50M	-4.45M
Investing Cash Flow	-539.00K	-1.16M	28.92M	-31.56M	-519.00K
Financing Cash Flow	9.00K	1.11M	1.87M	38.76M	4.46M

Collplant Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 2.4 is below the 20-day moving average (MA) of 2.65, below the 50-day MA of 2.61, and below the 200-day MA of 2.70, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 42.86 is Neutral, neither overbought nor oversold. The STOCH value of 23.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.

Collplant Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALGS	48 Neutral	$62.99M	―	-87.74%	―	-60.16%	―
CLGN	47 Neutral	$31.28M	―	-78.25%	―	248.62%	26.22%
PYPD	41 Neutral	$35.26M	―	-312.77%	―	―	61.18%
SNSE	40 Underperform	$11.86M	―	-67.47%	―	―	9.63%
ALXO	39 Underperform	$102.28M	―	-104.21%	―	―	39.60%
SPRB	35 Underperform	$4.84M	―	-133.62%	―	-86.43%	-8.91%

Collplant Holdings Corporate Events

CollPlant Expands VergenixSTR Distribution in Europe

On September 15, 2025, CollPlant Biotechnologies announced the expansion of its European distribution network for its VergenixSTR product by signing a new agreement in Poland. VergenixSTR, a soft tissue repair matrix designed to treat tendinopathy, combines rhCollagen with platelet-rich plasma to promote tendon healing. This expansion is part of CollPlant’s strategy to broaden its global distribution network, enhancing its market presence in Europe and the Asia-Pacific region.

CollPlant Biotechnologies Transfers Listing to Nasdaq Capital Market

CollPlant Biotechnologies Ltd. announced that it has successfully transferred the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 12, 2025. This move is part of the company’s strategic efforts to optimize its market positioning while maintaining the trading symbol ‘CLGN’. The transfer is expected to have no impact on the trading of its shares, ensuring continuity for investors and stakeholders.

CollPlant Biotechnologies Advances Dermal Filler Program and Reports Q2 2025 Financial Results

On August 20, 2025, CollPlant Biotechnologies reported its financial results for the second quarter of 2025, highlighting significant advancements in its photocurable dermal filler program and regenerative breast implant technology. The company is preparing for clinical studies of its dermal filler, which has shown promising results in preclinical testing, and is expanding its market presence with new appointments and collaborations. CollPlant also reported a decrease in GAAP revenues for the quarter compared to the previous year, but an increase in revenues for the first half of the year due to a milestone payment from AbbVie. The company’s efforts to expand its product distribution and enhance its market position in the regenerative medicine industry are ongoing, with a focus on non-animal-derived collagen solutions.

CollPlant Strengthens North American Operations with New Leadership

On July 14, 2025, CollPlant Biotechnologies announced the appointment of Bowman Bagley as Vice President, Commercial North America. This new role aims to enhance the company’s commercial strategy and market presence in North America, focusing on sales, marketing, and logistics for rhCollagen-based products. Bagley’s extensive experience in collagen-based biomaterials and his leadership roles in genomics and tissue engineering are expected to bolster CollPlant’s growth strategy, particularly in expanding their bioinks portfolio and rhCollagen sales. This strategic appointment is anticipated to drive long-term value for shareholders and strengthen CollPlant’s position in the regenerative and aesthetic medicine markets.